




**UNIVERSITÀ
DEGLI STUDI
DI TRIESTE**

OLIGONUCLEOTIDE APTAMERS AND THEIR USE AS ANTI-TUMOR AGENTS

New anti-tumor agents



Category:

Life Sciences

Patent Ownership:

UNIVERSITÀ DI TRIESTE

Inventors:

Gabriele GRASSI, Bruna SCAGGIANTE

Priority Date:

13th September 2010; 12th September 2011

Patent Application Number:

0001405761; PCT/EP2011/065738

Patent Status:

Granted in Italy, pending in Europe

Licensing Availability:

Available

Contacts:

Technology Transfer and Business Relations Office

E-mail: brevetti@amm.units.it

Ph: + 39 040 558 3821

Brief description

The invention concerns oligonucleotide aptamers with a GT sequence and its derivatives, which has a well-defined length, and their use as anti-tumor agents either by themselves or in association with other anti-tumor therapies.

Innovative aspects and main advantages

The invention involves the therapeutic use of such oligonucleotide aptamers as a new kind of antiproliferative anti-tumor agents against highly aggressive tumors and their diagnostic use as specific reagents for the detection of eEF1A proteins.

Applications

The oligonucleotide aptamer as per this invention may not only be put to therapeutic use, but also proves useful on a diagnostic level, since it is able to recognize eEF1A proteins.

Potential market

The whole pharmaceutical industry is a potential market for this invention.

Development status

Available for the market.

Università degli Studi di Trieste

Piazzale Europa, 1

I - 34127 Trieste

Tel. 040 558 3821

Mail: brevetti@amm.units.it

www.units.it/brevetti